|
|
PROGRAM - MONDAY, MAY 18, 2009 |
| 7:15AM-8:15 AM |
|
|
EDUCATIONAL SYMPOSIUM - Sponsored by UBC |
| |
|
The Comparative Effectiveness Research Wave: Solving Surfing Techniques
Symposium Description
|
| 7:15AM-8:15AM |
|
ISPOR SMALL GROUP MEETINGS/INVITATIONAL MEETINGS |
| |
|
|
| 8:00AM-8:30AM |
|
EXHIBITS & POSTER PRESENTATIONS VIEWING – SESSION I |
| |
|
|
| 8:30AM-8:45AM |
|
WELCOME & INTRODUCTION |
| |
|
 John Hornberger MD, MS, Program Planning Committee Chair and Principal, CEDAR Associates LLC and Adjunct Clinical Professor of Medicine, Stanford University School of Medicine, Menlo Park, CA, USA
|
| 8:45AM-9:00AM |
|
PRESIDENTIAL ADDRESS |
| |
|
 Chris L. Pashos PhD
2008-2009 ISPOR President and Vice President,
HERQuLES, Abt BioPharma Solutions, Inc., Lexington, MA, USA
|
| 9:00AM-10:00AM |
|
FIRST PLENARY SESSION |
| |
|
Health Metrics - Patient to Population: Getting it Right
Valid, reliable and comparable measurements of patient outcomes can be aggregated to the population level to help guide policy formulation. Policy salience of health outcome information is enhanced when it is integrated with measurement of the effective coverage of key public health and medical care interventions. Such information would markedly improve health policymaking over time. In many countries, including the USA, despite considerable investment in the collection of health information, the key metrics needed to inform policy formulation are often not available. Thus, these countries are unable to know, across the population as a whole, how people are faring on health and whether they are receiving the interventions that would make the greatest contribution to improved health. During this session, research in multiple countries on the comparable assessment of population health and intervention effective coverage will be presented.
9:00 – 9:10 AM |
 |
Moderator: Paul Kind, University of York, York, UK |
| 9:10 – 9:45 AM |
 |
Speaker: Christopher J. L. Murray DPhil, MD, Institute for Health Metrics & Evaluation & Professor of Global Health School of Medicine, University of Washington. Seattle, WA, USA |
9:45 – 10:00 AM |
Discussion |
|
| 10:00AM-10:30AM |
|
BREAK, EXHIBITS & POSTER PRESENTATIONS VIEWING – SESSION I |
| |
| 10:30AM-11:30AM
|
|
WORKSHOPS - SESSION I |
|
|
CLINICAL OUTCOMES RESEARCH |
| 10:30AM-11:30AM |
W1: INNOVATIONS IN PHYSIOLOGIC AND PATIENT-REPORTED DATA CAPTURE: IMPLICATIONS FOR STREAMLINING DATA COLLECTION AND LEVERAGING ACCESS TO REAL-TIME DATA
Discussion Leaders: Sonya Eremenco MA, ePRO Manager, United BioSource Corporation, Health Care Analytics, Bethesda, MD, USA; Wilhelm Muehlhausen DVM, Senior Product Manager ePRO, Cardinal Health Germany 234 GmbH, Research Services, Hoechberg, Germany; Lionel Tarassenko FREng, Professor of Electrical Engineering, University of Oxford, Institute of Biomedical Engineering, Oxford, UK; Jill V. Platko PhD, Scientific Advisor, PHT Corporation, Charlestown, MA, USA |
|
ECONOMIC OUTCOMES RESEARCH |
| 10:30AM-11:30AM |
W2: TRANSFERABILITY OF ECONOMIC EVALUATIONS FROM SETTING TO SETTING WITHIN THE UNITED STATES
Discussion Leaders: Michael F. Drummond DPhil, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Amy K O'Sullivan PhD, Associate Director, i3 Innovus, Medford, MA, USA; David W. Lee PhD, Senior Director, GE Healthcare, Health Economics and Outcomes Research, Waukesha, WI, USA |
|
PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH |
| 10:30AM-11:30AM |
W3: REVISITING THE ESTIMATION OF QALYS
Discussion Leaders: Benjamin M. Craig PhD, Assistant Faculty Member, Health Outcomes and Behavior, Moffitt Cancer Center and Courtesy Associate Professor of Economics, Univ. of South Florida, Moffitt Cancer Center, Health Outcomes and Behavior, Tampa, FL, USA; Jan J. Busschbach PhD, Senior Research Associate, Erasmus Medical Center, Department of Medical Psychology and Psychotherapy, Rotterdam, The Netherlands; Mark Oppe MSc, Researcher, Institute for Medical
Technology Assessment, Erasmus MC, Rotterdam, The Netherlands |
|
USE OF REAL WORLD DATA |
| 10:30AM-11:30AM |
W4: ASSESSING HETEROGENEITY OF TREATMENT EFFECTS
Discussion Leaders: Bijan J. Borah PhD, Senior Researcher, i3 Innovus, Eden Prairie, MN, USA; Nilay D. Shah PhD, Assistant Professor, Mayo Clinic, Division of Health Care Policy and Research, Rochester, MN, USA; Henry Joe Henk PhD, Director, i3 Innovus, Health Economics & Outcomes, Eden Prairie, MN, USA |
|
|
| 10:30AM-11:30AM |
W5: KEEPING VULNERABLE POPULATIONS SAFE FROM PERTUSSIS: USING MODELING TOOLS TO IDENTIFY COST-EFFECTIVE INTERVENTIONS FOR WHOOPING COUGH
Discussion Leaders: Amy L. Greer MSc, PhD, Research Fellow, Research Institute of the Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, ON, Canada; David F. Fisman MD, FRCPC, MPH, Medical Epidemiologist and Scientist, Ontario Agency for Health Protection and Promotion and The Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, ON, Canada; Marija Zivkovic Gojovic MSc, PhD Candidate, York University, Centre for Disease Modeling, Toronto, ON, Canada; Laurent Coudeville PhD, Health Economics Deputy Director, Sanofi Pasteur, Lyon, France |
|
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH |
| 10:30AM-11:30AM |
W6: FEASIBILITY OF INDIRECT COMPARISON ANALYSIS TO SUPPORT REIMBURSEMENT DECISIONS
Discussion Leaders: Cornelis Boersma MSc, PhD Student, and Director, University of Groningen, Department of Pharmacy, Unit of PharmaEpidemiology & PharmacoEconomics (PE2)/HECTA B.V, Groningen, The Netherlands; Lieven Annemans PhD, MSc, Professor of Health Economics, University of Ghent, Brussels University, Ghent, Belgium; Maarten J. Postma PhD, Professor Pharmacoeconomics, University of Groningen, Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Groningen, The Netherlands |
|
|
| 10:30AM-11:30AM |
W7: ADHERING TO MULTIPLE GUIDELINES FOR PREPARATION OF FORMULARY SUBMISSION DOSSIERS: ALIGNING WITH PAYER EXPECTATIONS
Discussion Leaders: Carol Gaich PharmD, RPh, HTA-Outcomes Liaison, Eli Lilly and Company, Indianapolis, IN, USA; Lynn Nishida RPh, Director, Clinical Pharmacy Services, The Regence Group/RegenceRx, Portland, OR, USA; Brian Sweet BSPharm, MBA, Chief Clinical Pharmacy Officer, WellPoint, Inc, Grand Island, NY, USA; Melissa Juniper MS, Director, Regulatory and Health Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA |
| 11:45AM-12:45PM |
|
ISPOR FORUMS (6 concurrent session) |
| 11:45AM-12:45PM |
|
A Checklist for Good Research Practices for the Application of Conjoint Analysis in Health Care Research Conjoint analysis and other patient preference methods are increasingly used in outcomes research as a means to identify and value aspects of health and health care. A checklist for good research practices for the application of conjoint analysis in outcomes research was developed and will be presented. This forum provides an opportunity to comment on this task force report.
Presented by the ISPOR Patient Preference Methods–Conjoint Analysis Task Force
Speakers: John F. P. Bridges PhD, Assistant Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; A. Brett Hauber PhD, Global Head, Health Preference Assessment, RTI Health Solutions and F. Reed Johnson PhD, Senior Fellow, RTI Health Solutions, Research Triangle, NC, USA
|
| 11:45AM-12:45PM |
Good Research Practices on Evaluating and Documenting the Content Validity of PRO Instruments to Support Medical Product Labeling
In 2006, the US FDA issued the Draft Guidance for Industry on Patient-Reported Outcome (PRO) Measures: Use in Medical Product Development to support Labeling Claims. Content validity is a critical measurement property of a PRO instrument when the instrument is used to produce evidence of treatment benefit to support claims in medical product labeling. Issues related to the selection and use of existing PRO measures in the context of providing evidence to support a labeling claim for medical products as well as topics that need to be considered when generating and presenting evidence to support adequate content validity of existing measures used as endpoints will be presented. This forum provides an opportunity to comment on the report on Good Research Practices on Evaluating and Documenting the Content Validity of PRO Instruments to Support Medical Product Labeling.
Presented by the ISPOR PRO Existing Instruments & Their Modification Task Force
Moderator & Speakers: Donald L. Patrick PhD, MSPH, University of Washington, Seattle, WA, USA; Charles Petrie PhD, Senior Director/Group Leader, Global Outcomes Research – Neuroscience, Pfizer, Ltd, New London, CT, USA; Pennifer Erickson PhD, Co-founder, OLGA, State College,
PA, USA |
| 11:45AM-12:45PM |
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses Although numerous pharmacoeconomic study guidelines are available in the literature, these guidelines are either vague or silent about how drug costs should be established or measured for cost effectiveness analyses(CEA). Recommendations for measuring drug costs for CEA from a societal, managed care, Medicare, Medicaid, industry, international perspectives will be presented and comment invited.
Presented by the ISPOR Drug Cost Task Force
Moderators: Joel W. Hay PhD, Co-Chair & Professor, Department of Clinical Pharmacy, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA, USA; James Smeeding RPh, MBA, Co-Chair & President, JestaRx Group, Dallas, Texas, USA
Speakers: Lou Garrison PhD, Societal Subgroup Chair & Professor and Associate Director, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA; C. Daniel Mullins PhD, Medicare Subgroup Chair & Professor and Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA; Brian Seal RPh, MBA, PhD, Medicaid Subgroup Chair & Senior-Director Health Outcomes Research, Internal Medicine and Oncology, Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA; Jack Mycka, Industry Subgroup Chair & Global President and CEO, MME LLC, Montclair, NJ, USA; Lizheng Shi PhD, MS, International Subgroup Chair & Assistant Professor, Department of Health Systems Management, Tulane University School of Public Health and Tropical Medicine,
New Orleans, LA, USA |
| 11:45AM-12:45PM |
Good Research Practices on the Design And Analysis Of Non-Randomized Studies Of Treatment Effects Using Secondary Databases
Non-randomized studies of treatment effects using secondary databases may supplement the evidence base from randomized clinical trials. Recognizing the challenges to conducting valid epidemiologic studies of this type, a good research practices for retrospective database studies addressing issues of framing research questions, design, analysis, reporting and interpretation of findings was developed with over 30 explicit recommendations identified. This forum provides an opportunity to comment on the report on Good Research Practices on the Design And Analysis Of Non-Randomized Studies Of Treatment Effects Using Secondary Databases
Presented by the ISPOR Good Research Practices for the Retrospective Database Studies Task Force |
|
|
| 11:45AM-12:45PM |
Health Care Decision Makers around the World : A Global Road Map and Country–specific Decision-Making and Reimbursement Processes
Country-specific and organization-specific health coverage decision making, reimbursement systems and pricing approval processes with emphasis on USA systems using the ISPOR Global Health Care Systems Road Map will be presented. This forum provides an opportunity to comment on the ISPOR Global Health Care Systems Road Map.
Presented by the Global Health Care Reimbursement Systems and Decision Processes Working Group of ISPOR HTA Special Interest Group
Moderator: Sheryl Szeinbach BS, MS, PhD, RPh, Professor, College of Pharmacy, Ohio State University, Columbus, OH USA; Speakers: Stefan Holmstrom BSc, MSc, Director Project Management, HE&OR, NicOx SA, Antipolis- cedex, France; Noreen Sullivan BS, President and CEO Technology Assessment Evaluation Group LLC, Encinitas, CA, USA; Kevin Mayo PhD, Vice President Market Access Solutions, Bridgehead International Consulting, Denville, NJ, USA
|
| 11:45AM-12:45PM |
ISPOR Student Forum: Key Drivers for a Career in Outcomes Research
How does a student prepare to succeed in a future pharmacoeconomics and outcomes research career? What characteristics and skills make a successful researcher in pharmacoeconomics and outcomes? What are the biggest challenges for industry, academia, and consulting careers? An expert panel from diverse work environments will discuss these critical questions.
Organized by the ISPOR Student Council
Moderators & Speakers: Zeba Khan PhD, RPh, ISPOR Director 2008-10 and Vice President, Pricing and Market Access, Celgene Pharmaceuticals, Summit, NJ, USA; Caitlyn Wilke, MS, Student Network Chair 2008-09 and Graduate Student, Pharmacoeconomic and Outcomes Research Fellow, University of Illinois at Chicago, Chicago, IL, USA; Chris Pashos PhD, ISPOR President 2008-09 and Vice President, Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA; Michael Drummond PhD, Professor of Health Economics, University of York, York, UK;
Todd Williamson MSc, Vice President, Health Economics, Outcomes & Reimbursement, Bayer Healthcare Pharmaceuticals, Wayne, NJ, USA; John Watkins RPh, MPH, Pharmacy Manager, Formulary Development, Premera Blue Cross, Bothell, WA USA
|
| |
| 12:45PM-2:30PM |
|
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I |
| |
|
|
| 1:15PM-2:15PM |
|
EDUCATIONAL SYMPOSIUM - Sponsored by IMS |
| |
|
Striving Towards a New Value Equation: The Need to Integrate Pricing & Reimbursement and Health Economics & Outcomes Research to Support Various Stakeholders in Improving Health Care Systems
Symposium Description
|
| 2:30PM-3:30PM |
|
ISSUE PANELS - SESSION I (5 concurrent session) |
| |
|
CLINICAL OUTCOMES RESEARCH ISSUES |
| 2:30PM-3:30PM |
IP1: WHAT IS THE ROLE FOR PRAGMATIC TRIALS IN REGULATORY APPROVAL?
Moderator: Penny Mohr MA, Vice President, Programs, Center for Medical Technology Policy, Baltimore, MD, USA Panelists: Marc L. Berger MD, Vice President, Eli Lilly, Global Health Outcomes, Indianapolis, IN, USA; Robert Temple MD, Director, Office of Drug Evaluation I, Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA |
| |
ECONOMIC OUTCOMES RESEARCH ISSUES |
| 2:30PM-3:30PM |
IP2: MODEL CALIBRATION: LOCUS FOCUS OR HOCUS POCUS?
Moderator: David Thompson PhD, Vice President, i3 Innovus, Health Economics and Outcomes Research, Medford, MA, USA Panelists: Milton C. Weinstein PhD, Professor, Health Policy and Management, Harvard School of Public Health, Boston, MA, USA; Alistair McGuire PhD, Chair in Health Economics, LSE Health and Social Care, London, UK |
| |
PATIENT-REPORTED OUTCOMES RESEARCH ISSUES |
| 2:30PM-3:30PM |
IP3: COMPARISONS BETWEEN THE MEDICATION POSSESSION RATIO (MPR) AND GAPS MEASURES OF MEDICATION COMPLIANCE: ARE WE SELLING OURSELVES SHORT BY RELYING ON THE MPR?
Moderator: Femida Gwadry-Sridhar BScPhm, MSc, PhD, Assistant Professor, University of Western Ontario, Department of Medicine, London, ON, Canada. Panelists: Elizabeth Manias MPharm, PhD, Professor, Associate Head of Research, The University of Melbourne, School of Nursing and Social Work, Carlton, Australia; Vernon F. Schabert PhD, Senior Director, IMS Consulting, Health Economics and Outcomes Research, Santa Barbara, CA, USA; Dyfrig Hughes PhD, MRPharmS, Deputy Director, Centre for Economics and Policy in Health, IMSCaR, Bangor University, Bangor, Wales LL57 1UT. |
| |
|
| 2:30PM-3:30PM |
IP4: MODELS FOR COLLABORATIVE DEVELOPMENT OF PATIENT-REPORTED OUTCOME MEASURES FOR CLINICAL TRIALS - DIFFERENT PATHS, SAME DESTINATION?
Moderator: Asha Hareendran PhD, Senior Research Scientist, United BioSource Corporation, London, UK
Panelists: Priti Jhingran PhD, US Health Outcomes Director, GlaxoSmithKline, Research Triangle Park, NC, USA; Dennis A. Revicki PhD, Director, United BioSource Corporation, Center for Health Outcomes Research, Bethesda, MD, USA |
| |
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES |
| 2:30PM-3:30PM |
IP5: ASSESSMENT AND APPRAISAL OF CANCER MEDICINES: DO THEY DESERVE A SPECIAL TREATMENT?
Moderator: Michael F. Drummond DPhil, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Panelists: Adrian Towse MPhil, Director, Office of Health Economics, London, UK; Mark Sculpher PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Scott Ramsey MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Seattle, WA, USA |
| 3:45PM-4:45PM |
|
RESEARCH PODIUM PRESENTATIONS – SESSION I (5 concurrent sessions) |
| 3:45PM-4:45PM |
|
HEALTH CARE DECISION-MAKER’S CASE STUDIES I |
| |
|
|
| |
|
|
| |
|
|
| 3:45PM-4:45PM |
|
CANCER - OUTCOMES RESEARCH STUDIES |
| |
|
| CN1: RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING |
| Lafeuille MH1, Bailey R2, Vekeman F1, Piech CT2, McKenzie RS2, Lefebvre P1 |
| 1 Groupe d'Analyse, Ltée, Montréal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA |
|
|
| |
|
| CN2: WHEN IS CANCER CARE COST-EFFECTIVE? A SYSTEMATIC OVERVIEW OF COST-UTILITY ANALYSES IN ONCOLOGY |
| Greenberg D1, Earle C2, Fang C1, Eldar-Lissai A3, Neumann PJ1 |
| 1Tufts Medical Center, Boston, MA, USA, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 3University of Rochester, Rochester, NY, USA |
|
| |
|
| CN3: ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH CARE COSTS ASSOCIATED WITH COLORECTAL CANCER |
| Rahman M1, Weinstein R2, Wilcox M2, Matcho A2, Wong S1 |
| 1Ortho Clinical Diagnostics, Raritan, NJ, USA, 2PRD USA, Titusville, NJ, USA |
|
| |
|
| CN4: LEVERAGING MULTIPLE DATA SOURCES TO EVALUATE COST AND SURVIVAL IN FOLFOX OR FOLFIRI TREATED STAGE IV COLORECTAL CANCER PATIENTS |
| Harley C1, Seal B2, Shetty S3, Nelson
M1 |
| 1i3 Innovus, Eden Prairie, MN, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3UnitedHealthcare, Edina, MN, USA |
|
| 3:45PM-4:45PM |
|
DRUG UTILIZATION STUDIES |
| |
|
| DU1: PHYSICAL FUNCTION AND THE CONCOMITANT USE OF ANTICHOLINERGIC ANTIHISTAMINES AND CHOLINESTERASE INHIBITORS AMONG MEDICAID RECIPIENTS WITH DEMENTIA |
| Modi A1, Craig B1, Weiner M2, Sands L1, Thomas J1 |
| 1Purdue University, West Lafayette, IN, USA, 2Indiana University, Indiana University Center for Aging Research and Regenstrief Institute Inc, Indianapolis, IN, USA |
|
| |
|
|
| |
|
| DU3: PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE CLAIMS DATA |
| Vekeman F1, Laliberte F1, Afonja O2, Lafeuille MH1, Barghout V2, Duh MS3, Skarin AT4 |
| 1Groupe d'analyse, Ltee, Montréal, QC, Canada, 2Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA, 3Analysis Group, Inc, Boston, MA, USA, 4Dana-Farber Cancer Institute, Boston, MA, USA |
|
| |
|
| DU4: THE IMPACT OF
DEMOGRAPHICS AND INSURANCE ON QUALITY OF CARE IN PATIENTS WITH
MAJOR DEPRESSIVE DISORDER IN A CALIFORNIA MEDICAID PROGRAM |
| Nichol MB1, Wu J1,
Knight TK1,
Priest JL2,
Cantrell CR2 |
| 1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA |
|
| 3:45PM-4:45PM |
|
PERSONALIZED MEDICINE |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| 3:45PM-4:45PM |
|
RESEARCH ON METHODS - UTILITY METHODS |
| |
|
|
| |
|
| UT2: ELICITING TIME TRADE-OFF AMOUNTS FOR HEALTH STATES IN HYPOTHETICAL INDIVIDUALS OF DIFFERENT AGES USING A DISCRETE CHOICE EXPERIMENT |
| Prosser LA1, Rusinak D2, Payne K3, Shi P2, Uyeki TM4, Messonnier M4 |
| 1University of Michigan, Ann Arbor, MI, USA, 2Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA, USA, 3University of Manchester, Manchester, UK, 4Centers for Disease Control and Prevention, Atlanta, GA, USA |
|
| |
|
|
| |
|
|
| |
|
|
| 5:00PM-6:00PM |
|
RESEARCH PODIUM PRESENTATIONS – SESSION II (5 concurrent session) |
| 5:00PM-6:00PM |
|
HEALTH CARE
DECISION-MAKER’S CASE STUDIES II |
| |
|
|
| |
|
| CASE5: PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: A CASE STUDY OF ERLOTINIB AT A MAJOR CANCER CENTER |
| Lal LS1, Ugwu C2, DaCosta Byfield S1, Miller LA1, Arbuckle R1 |
| 1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2University of Houston, Houston, TX, USA |
|
| |
|
| CASE6: PILOT PROJECT: INTEGRATING ADMINISTRATIVE AND FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS |
|
Wong H1, Levit K2,
Sun YC3 |
| 1Agency for Healthcare Research and Quality, Rockville, MD, USA, 2Thomson Reuters/Agency for Healthcare Research and Quality, Washington, DC, USA, 3Thomson Reuters, Santa Barbara, CA, USA |
|
| 5:00PM-6:00PM |
|
RESEARCH ON METHODS - COST & CLINICAL OUTCOMES METHODS |
| |
|
|
| |
|
|
| |
|
| CO3: ESTIMATING DRUG COSTS IN ECONOMIC EVALUATIONS IN IRELAND AND THE UK: AN ANALYSIS OF PRACTICE AND RESEARCH RECOMMENDATIONS |
| Hughes DA1, Tilson L2, Drummond MF3 |
| 1Bangor University, Bangor, UK, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 3University of York, York, Heslington, UK |
|
| |
|
| CO4: COMPARISON OF INPATIENT COST ESTIMATION METHODS: USING DATA FROM A CYSTIC FIBROSIS TRIAL |
| Dinan M1, Morgan Dewitt E2, Grussemeyer C1, Reed SD1 |
| 1Duke Clinical Research Institute, Durham, NC, USA, 2Duke University, Durham, NC, USA |
|
| 5:00PM-6:00PM |
|
CARDIOVASCULAR DISORDERS - OUTCOMES RESEARCH STUDIES |
| |
|
| CV1: ASSOCIATION OF CARDIOMETABOLIC RISK FACTORS AND PREVALENT CARDIOVASCULAR EVENTS |
| Malone DC1, Boudreau D2, Nichols G3, Raebel MA4, Fishman P5, Feldstein A3, Ben-Joseph R6, Okamoto LJ7 |
| 1University of Arizona College of Pharmacy, Tucson, AZ, USA, 2United BioSource Corporation, Seattle, WA, USA, 3Kaiser Permanente, Portland, OR, USA, 4Kaiser Permanente Colorado, Denver, CO, USA, 5Group Health, Seattle, WA, USA, 6Sanofi-Aventis, Bridgewater, NJ, USA, 7United BioSource Corporation, Bethesda, MD, USA |
|
| |
|
|
| |
|
|
| |
|
| CV4: ASPIRIN VERSUS CLOPIDOGREL IN COMBINATION WITH PROTON-PUMP INHIBITORS FOR PREVENTION OF RECURRENT PEPTIC ULCER COMPLICATIONS IN PATIENTS WITH PREVIOUS GASTROINTESTINAL BLEEDING |
| Hsiao FY1, Tsai YW2, Huang WF3, Wen YW4, Chen PF4, Chang PY3, Kuo KN4 |
| 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2National Health Research Institutes, Zhunan Town, Taiwan, 3National Yang-Ming University, Taipei, Taiwan, 4National Health Research Institutes, Miaoli County, Taiwan |
|
| 5:00PM-6:00PM |
|
FORMULARY DEVELOPMENT STUDIES |
| |
|
|
| |
|
|
| |
|
| FD3: CONCEPTUAL ISSUES IN THE DEVELOPMENT OF A MEASURE OF FORMULARY CULTURE |
| Duhig J1, Edison M1, Galanter W1, Koronkowski M1, Lambert BL1, Lodolce A1, Pickard AS2, Wilke CT2, Schiff G3 |
| 1University of Illinois at Chicago, Chicago, IL, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3Brigham and Women's Hospital, Boston, MA, USA |
|
| |
|
|
| 5:00PM-6:00PM |
|
VACCINATION - OUTCOMES RESEARCH STUDIES |
| |
|
| VA1: A MARKOV MODEL EXAMINING THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF MASS VACCINATION USING LIVE ATTENUATED HUMAN ROTAVIRUS VACCINE IN A DEVELOPING ASIAN COUNTRY |
| Rose J1, Molnar RL1, Watts B2, Singer ME1 |
| 1Case Western Reserve University School of Medicine, Cleveland, OH, USA, 2Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH, USA |
|
| |
|
| VA2: COST EFFECTIVENESS ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN CANADA |
| Ismaila AS1, Pereira JA1, Robson RC1, Simpson SD1, Rawson NS1, Standaert BA2 |
| 1GlaxoSmithKline, Mississauga, ON, Canada, 2GlaxoSmithKline Biologicals, Rixensart, Belgium |
|
| |
|
| VA3: A GLOBAL COST-EFFECTIVENESS EVALUATION OF THE IMPACT OF POTENTIAL INNOVATIONS IN MEASLES VACCINATION |
| Garrison LP1, Bauch CT2, Bresnahan BW1, Hazlet TK1, Kadiyala S1, Veenstra DL1 |
| 1University of Washington, Seattle, WA, USA, 2University of Guelph, Guelph, ON, Canada |
|
| |
|
|
| 6:00PM-6:30PM |
|
ISPOR ANNUAL BUSINESS MEETING |
| |
|
Call To Order: Chris L. Pashos PhD, 2008-2009 ISPOR President
Executive Director’s Report: Marilyn Dix Smith PhD, ISPOR Executive Director
Treasurer’s Report: Karen Rascati PhD, ISPOR Treasurer
Value In Health Editor-In-Chief Report: Josephine Mauskopf PhD, Value in Health Editor-in-Chief
ISPOR CONNECTIONS Editors-In-Chief Report: Thomas Mittendorf PhD and David Thompson PhD
Member Open Discussion: ISPOR Members
New Business: Chris L. Pashos PhD, 2008-2009 ISPOR President
|
| 6:00PM-7:00PM |
|
POSTER AUTHOR DISCUSSION HOUR - SESSION I |
| |
|
|
| 6:00PM-8:00PM |
|
EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I |
|
|
